VEGF antagonist formulations
First Claim
Patent Images
1. A stable liquid formulation of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist, comprising 10-100 mg/ml of a fusion protein comprising amino acids 27-457 of SEQ ID NO:
- 4, and a multimerizing component;
5 mM phosphate and 5 mM citrate, at a pH of about 6.0-6.5;
about 20% sucrose;
about 50-100 mM NaCl; and
about 0.1% polysorbate 20;
wherein at least 92% of the fusion protein antagonist is present in native conformation as measured by SE-HPLC following storage at 5°
C. for 12 months.
1 Assignment
0 Petitions
Accused Products
Abstract
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
44 Citations
5 Claims
-
1. A stable liquid formulation of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist, comprising 10-100 mg/ml of a fusion protein comprising amino acids 27-457 of SEQ ID NO:
- 4, and a multimerizing component;
5 mM phosphate and 5 mM citrate, at a pH of about 6.0-6.5;
about 20% sucrose;
about 50-100 mM NaCl; and
about 0.1% polysorbate 20;
wherein at least 92% of the fusion protein antagonist is present in native conformation as measured by SE-HPLC following storage at 5°
C. for 12 months. - View Dependent Claims (2, 3, 4, 5)
- 4, and a multimerizing component;
Specification